LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Stock List・Ardelyx Inc

Ardelyx Inc

Closed

SectorHealthcare

6.61 0.15

Buy Sell

Overview

Share price change

24h

Current

Min

6.47

Max

6.68

Key metrics
By Trading Economics
Income	-37M -38M
Sales	-31M 94M
EPS	-0.15
Profit margin	-39.805
Employees	489
EBITDA	-42M -32M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+151.13% upside

Dividends
By Dow Jones
Next Earnings	3 Aug 2026

Market Stats
By TradingEconomics
Market Cap	334M 1.8B
Previous open	6.46
Previous close	6.61

News Sentiment

By Acuity

26%

74%

83 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

3.62 / 3.95 Support & Resistance

Ardelyx Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 May 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 May 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 May 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 May 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 May 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 May 2026, 22:32 UTC

Earnings

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 May 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 May 2026, 21:49 UTC

Earnings

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 May 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 May 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 May 2026, 21:23 UTC

Acquisitions, Mergers, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 May 2026, 21:12 UTC

Earnings

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 May 2026, 21:12 UTC

Earnings

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 May 2026, 20:44 UTC

Earnings

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 May 2026, 20:43 UTC

Earnings

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 May 2026, 20:32 UTC

Earnings

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 May 2026, 20:32 UTC

Earnings

CleanSpark 2Q Rev $136.4M >CLSK

11 May 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Cont Ops EPS $2.24 >STE

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Rev $1.6B >STE

11 May 2026, 20:30 UTC

Earnings

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Adj EPS $2.83 >STE

11 May 2026, 20:22 UTC

Hot Stocks

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 May 2026, 19:37 UTC

Earnings

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 May 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Comparison

Price change

Ardelyx Inc Forecast

Price Target

By TipRanks

151.13% upside

12 Months Forecast

Average 16.6 USD 151.13%

High 19 USD

Low 13 USD

Based on 5 Wall Street analysts offering 12 month price targets forArdelyx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Ardelyx Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.62 / 3.95Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

83 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.